News
FDA asks Sarepta to stop shipping gene therapy
Digest more
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback